Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MDXG logo MDXG
Upturn stock ratingUpturn stock rating
MDXG logo

MiMedx Group Inc (MDXG)

Upturn stock ratingUpturn stock rating
$7.15
Last Close (24-hour delay)
Profit since last BUY4.38%
upturn advisory
Consider higher Upturn Star rating
BUY since 16 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: MDXG (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $12.2

1 Year Target Price $12.2

Analysts Price Target For last 52 week
$12.2 Target price
52w Low $5.47
Current$7.15
52w High $10.14

Analysis of Past Performance

Type Stock
Historic Profit 24.56%
Avg. Invested days 31
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.06B USD
Price to earnings Ratio 34.05
1Y Target Price 12.2
Price to earnings Ratio 34.05
1Y Target Price 12.2
Volume (30-day avg) 5
Beta 1.79
52 Weeks Range 5.47 - 10.14
Updated Date 08/15/2025
52 Weeks Range 5.47 - 10.14
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.21

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-07-29
When Before Market
Estimate 0.054
Actual 0.1

Profitability

Profit Margin 8.84%
Operating Margin (TTM) 12.55%

Management Effectiveness

Return on Assets (TTM) 10.37%
Return on Equity (TTM) 16.61%

Valuation

Trailing PE 34.05
Forward PE 19.53
Enterprise Value 957501824
Price to Sales(TTM) 2.91
Enterprise Value 957501824
Price to Sales(TTM) 2.91
Enterprise Value to Revenue 2.63
Enterprise Value to EBITDA 18.16
Shares Outstanding 147959008
Shares Floating 109563948
Shares Outstanding 147959008
Shares Floating 109563948
Percent Insiders 1.7
Percent Institutions 71.51

ai summary icon Upturn AI SWOT

MiMedx Group Inc

stock logo

Company Overview

overview logo History and Background

MiMedx Group Inc. was founded in 2008. It focuses on developing and marketing regenerative biomaterial products and therapies derived from human placental tissue. The company experienced significant growth followed by accounting controversies, resulting in a restatement of financials and changes in leadership.

business area logo Core Business Areas

  • Wound Care: This segment offers advanced wound care products derived from placental tissue for chronic and acute wounds.
  • Surgical & Sports Medicine: This segment provides regenerative products used in surgical procedures and sports medicine applications, focusing on tissue repair and regeneration.

leadership logo Leadership and Structure

The company has a board of directors overseeing executive management. The current CEO is Joseph H. Ciavarella. The organizational structure includes departments for R&D, sales and marketing, operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • EpiFix: A dehydrated human amnion/chorion membrane (dHACM) allograft used for wound healing. Competitors include Integra LifeSciences (IART), Organogenesis (ORGO), and Smith & Nephew (SNN). Specific market share data is difficult to pinpoint precisely due to varying market definitions and limited disclosures, but EpiFix is a significant player in the advanced wound care market.
  • AmnioFix: A dHACM allograft used in surgical and sports medicine applications. Competitors include Osiris Therapeutics (acquired by Smith & Nephew), and other companies offering biological scaffolds for tissue repair. Similar to EpiFix, specific market share data is challenging to obtain, but AmnioFix holds a prominent position in its target market.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine and advanced wound care markets are experiencing growth driven by aging populations, increasing prevalence of chronic diseases (e.g., diabetes), and advancements in biomaterial technologies.

Positioning

MiMedx aims to be a leader in regenerative biomaterials derived from placental tissue. Their competitive advantage lies in their proprietary processing techniques and established clinical evidence.

Total Addressable Market (TAM)

The total addressable market for wound care and surgical biologics is estimated to be in the billions of dollars globally. MiMedx is positioned to capture a portion of this market through its existing product portfolio and ongoing R&D efforts.

Upturn SWOT Analysis

Strengths

  • Proprietary processing technology
  • Established clinical evidence for products
  • Strong brand recognition within specific segments
  • Experienced leadership team (current)

Weaknesses

  • Past accounting controversies and legal challenges
  • Reliance on a limited number of key products
  • Pricing pressure from competitors
  • Potential regulatory hurdles

Opportunities

  • Expansion into new geographic markets
  • Development of new product applications
  • Strategic partnerships and acquisitions
  • Increasing adoption of regenerative medicine therapies

Threats

  • Intense competition in the advanced wound care market
  • Changes in reimbursement policies
  • Potential product liability claims
  • Emergence of disruptive technologies

Competitors and Market Share

competitor logo Key Competitors

  • IART
  • ORGO
  • SNN

Competitive Landscape

MiMedx faces strong competition from established players in the advanced wound care and surgical biologics markets. Their success depends on differentiating their products through clinical data, pricing strategies, and customer service.

Major Acquisitions

None

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: No major acquisitions in recent years.

Growth Trajectory and Initiatives

Historical Growth: Historical growth was significant prior to the accounting restatement, followed by a period of recovery and rebuilding.

Future Projections: Future growth projections depend on successful execution of their strategic plan and market conditions. Analyst estimates vary.

Recent Initiatives: Recent initiatives include new product launches, expansion of the sales force, and efforts to improve operational efficiency and compliance.

Summary

MiMedx is a regenerative medicine company focused on placental-derived biomaterials. The company has had challenges but is now focusing on sustainable growth. Their proprietary technologies and strong clinical evidence are key strengths. Future performance depends on successfully navigating the competitive landscape and executing their strategic plan.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Market Reports
  • Analyst Estimates
  • Company Website

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MiMedx Group Inc

Exchange NASDAQ
Headquaters Marietta, GA, United States
IPO Launch date 2007-08-22
CEO & Director Mr. Joseph H. Capper
Sector Healthcare
Industry Biotechnology
Full time employees 837
Full time employees 837

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.